Iron chelation therapy for children with transfusion‐dependent β‐thalassemia: How young is too young?

Abstract

AbstractIn this review, we provide a summary of evidence on iron overload in young children with transfusion‐dependent β‐thalassemia (TDT) and explore the ideal timing for intervention. Key data from clinical trials and observational studies of the three available iron chelators deferoxamine, deferiprone, and deferasirox are also evaluated for inclusion of subsets of young children, especially those less than 6 years of age. Evidence on the efficacy and safety of iron chelation therapy for children ≥2 years of age with transfusional iron overload is widely available. New data exploring the risks and benefits of early‐start iron chelation in younger patients with minimal iron overload are also emerging.